Today Digital – Foundation Warns Against the Increase in Hepatitis B and C in R & D

The Foundation of patients with hepatitis B and C and other immunological diseases in the Dominican Republic (Funpaheinm) expressed the need to be tested to detect the virus and identify people who undergo, and submit to treatments to comply with the goal of the World Health Organization (WHO), to eradicate it by 2030.
By intervening in On the occasion of the World Day of Combating Hepatitis, which was commemorated on Saturday, Funpaheinm President, Arleen Cestari of Genao, said that the increase the number of new patients going to certified hospitals affected by the hepatitis B and C viruses is an indicator that attention should be given to the issue.
Alert. He pointed out that this non-profit institution required medical authorities, especially the National Health Service, pharmaceutical laboratories that produce drugs for hepatitis, the media, businesses and other sectors that affect the system, the implementation of educational campaigns and the dissemination of information to the public about the need to be tested for hepatitis.

"It is only in this way that people with hepatitis can be identified and, in most cases, carriers who do not know their situation because it is a a disease that has symptoms in the very advanced stages where, probably, nothing can be done to treat it, "said Cestari de Genao.

Funpaheinm's president said" although the high-cost Ministry of Public Health provide new therapy with four treatment units In the same number of hospitals, it is estimated that unidentified people with hepatitis B or C viruses are much more than identified patients until now;
Sandra Cabrera Febrillet, Medical Advisor of Funpaheinm, also spoke about the origin of the institution and the work done by the founding members who accompanied this task, valuing the work of the current advice as very positive.

Specialists. In the event mentioned above also took the floor, Fernando Contreras (gastroenterologist), who spoke about "hepatitis C: path to its elimination"; and Giselle Vásquez, Director of the High Cost Medicines Program of the Ministry of Public Health. In his dissertation, the health professional addressed "progress in treating hepatitis C in the high-cost drug program."